Edition:
United States

Alder Biopharmaceuticals Inc (ALDR.OQ)

ALDR.OQ on NASDAQ Stock Exchange Global Market

10.60USD
3:59pm EST
Change (% chg)

$-0.05 (-0.47%)
Prev Close
$10.65
Open
$10.50
Day's High
$10.77
Day's Low
$10.38
Volume
173,894
Avg. Vol
297,139
52-wk High
$29.95
52-wk Low
$8.68

Select another date:

Tue, Nov 7 2017

BRIEF-Alder Biopharmaceuticals Q3 loss per share $0.92

* Alder biopharmaceuticals announces third quarter 2017 financial and operating results

BRIEF-Alder Biopharmaceuticals Q2 loss per share $1.48

* Alder Biopharmaceuticals announces second quarter 2017 financial and operating results

BRIEF-Alder Biopharmaceuticals announces commencement of public offering of common stock

* Alder Biopharmaceuticals, Inc. announces commencement of public offering of common stock

Alder's shares tumble as migraine drug data disappoints

Alder BioPharmaceuticals Inc's late-stage study data on its experimental treatment to prevent episodic migraine fell short of investor expectations, sending its shares plunging as much as 26 percent to a more than two-and-half year low.

UPDATE 4-Alder's shares tumble as migraine drug data disappoints

* Shares fall as much as 26 pct to 2 1/2 yr-low (Adds analyst comment, updates shares)

BRIEF-Alder Biopharmaceuticals announces positive eptinezumab phase 3 results

* Alder Biopharmaceuticals announces positive eptinezumab phase 3 results for prevention of frequent episodic migraine

Alder's migraine drug meets main goal in late-stage study

June 27 Alder BioPharmaceuticals Inc said on Tuesday its experimental treatment to prevent episodic migraine met the main goal of reducing monthly migraine days in a late-stage study.

Select another date: